Moderna and rovi expand long-term collaboration for the manufacture of mrna medicines over the next ten years

Long-term agreement includes a series of investments to acquire new equipment and adapt the present rovi drug product fill-finish facilities and production lines in spain cambridge, ma and madrid, spain / accesswire / february 16, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, and laboratorios farmacÉuticos rovi, s.a. (bme: rovi), a pan-european pharmaceutical company specializing and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties, today announced a long-term collaboration to increase capacities for the compounding, aseptic filling, inspection, labeling, and packaging of rovi's facilities, located in madrid, san sebastiÁn de los reyes and alcalÁ de henares.
MRNA Ratings Summary
MRNA Quant Ranking